Back to today’s briefing

Story perspectives

Breakthrough AI Therapy Trial Launched for Rare Genetic Disorder

2/25/2025

33 5

Summary

Healx Initiates Trial

Healx has launched a Phase 2 trial for HLX-1502, an innovative AI-discovered therapy targeting neurofibromatosis type 1 (NF1), a rare genetic disorder impacting 1 in 2,500 individuals. This groundbreaking trial, involving 20 patients, seeks to offer safer treatment options, representing a hopeful leap forward in the care of NF1.

Summary

Researchers Restore Vision

A groundbreaking gene therapy developed by researchers at University College London and Moorfields Eye Hospital has given new hope to children suffering from AIPL1-related retinal dystrophy, a devastating genetic disorder leading to blindness. Remarkably, four young patients have experienced partial vision restoration, showcasing significant progress over three to four years and paving the way for future treatments of genetic blindness.

1 of 2

Healx Initiates Trial

Healx has launched a Phase 2 trial for HLX-1502, an innovative AI-discovered therapy targeting neurofibromatosis type 1 (NF1), a rare genetic disorder impacting 1 in 2,500 individuals. This groundbreaking trial, involving 20 patients, seeks to offer safer treatment options, representing a hopeful leap forward in the care of NF1.

1 / 2